#Israel #Liver Disease #Galmed Pharmaceuticals #Ramat-Gan #Aramchol Meglumine

Galmed Pharmaceuticals' Major Breakthrough

Galmed Pharmaceuticals Ltd., a company specializing in clinical-stage biopharmaceuticals for treating liver diseases and gastrointestinal oncology, recently made headlines with the release of unparalleled findings from its Phase 1 pharmacokinetics (PK) study, identified as Study AM-001. The study evaluated the oral formulation of Aramchol Meglumine (AM) and demonstrated that a 400mg dosage significantly enhances bioavailability—up to approximately 500%—when compared to the traditional 300mg Aramchol Free Acid (AA). This pivotal advancement will not only pave the way for enhanced patient convenience and compliance but could potentially reduce the cost of goods sold by 50%.

Study Objectives and Key Findings

The primary objective of the AM-001 study was to establish the optimal dosage of Aramchol Meglumine that would provide bioavailability equivalent to that of the AA formulation, while allowing for simplified dosing. Participants were administered single doses of the 400mg and 200mg AM granules in comparison with the 300mg AA tablet dosed twice daily. The results revealed a stark increase in bioavailability; the 400mg AM granules were shown to deliver 5 times the exposure compared to AA, while the 200mg did so at a ratio of approximately 3 times.

“This represents a critical step forward, as a once-daily administration of a lower dose is key for patient adherence,” stated Allen Baharaff, Co-founder and CEO of Galmed. The increase in bioavailability is anticipated to not only enhance the drug's efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) but also will be instrumental in the company’s ongoing pre-clinical studies aimed at addressing drug resistance in cancer treatments.

Implications of the Findings

Aramchol operates by inhibiting stearoyl-CoA desaturase 1 (SCD1), a regulator in key metabolic processes within liver cells and other tissues, contributing to diseases such as MASH, which is a serious form of fatty liver disease that can progress to cirrhosis or liver failure. The earlier clinical trials, including Phase 2 and an open-label Phase 3 study, have demonstrated promising outcomes, indicating that a 600mg dose of Aramchol notably reduced liver fat and provided robust anti-fibrotic effects. As of now, data shows that about 600 individuals, comprising of both healthy participants and those afflicted with MASH, have successfully received doses of Aramchol.

Future Directions

Looking forward, the company is gearing up for a clinical trial evaluating the once-daily administration of AM against AA in an ongoing PK study named AM-003. The implications of these results are considerable, especially when expanding Galmed’s research into oncology, where the strategic development of Aramchol could address unmet needs in gastrointestinal cancers.

Galmed’s efforts to broaden its scope include pursuing advancements in cardiometabolic and neurological medical indications, showcasing the company’s commitment to innovation within its therapeutic pipeline. As stated by Baharaff, “A higher exposure is vital to exploit Aramchol's full potential beyond its initial applications in MASH.”

Navigating through the complexities of pharmacokinetics, Galmed has positioned Aramchol not only as a promising treatment for liver diseases but also as a significant player in the broader landscape of oncological therapies. This breakthrough could ultimately lead to transformative changes in how metabolic diseases and certain cancers are managed.

Conclusion

In conclusion, Galmed Pharmaceuticals is not merely continuing its legacy in treating liver diseases but is also on track to revolutionize the therapeutic approach to cancer care. The latest findings regarding Aramchol are potentially a game-changer, reflecting the intersection of innovation, patient-centric care, and the pursuit of effective treatment modalities. As the landscape of biopharmaceuticals continues to evolve, Galmed stands at the forefront with its advancements, setting a high bar for future developments in the industry.